Michael H. Kim

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Michael H. Kim, Michael H Kim
Publication record
100 papers · 2,009 citations · H-index 18

PAPERS

Role of Connexin 43 phosphorylation on Serine-368 by PKC in cardiac function and disease
202324 citationsauthor #2
Incremental healthcare cost burden in patients with atrial flutter only
20230 citationsauthor #4
RELATIONSHIP OF HEALTH-RELATED SOCIAL NEEDS, SOCIAL DETERMINANTS OF HEALTH AND HOSPITAL READMISSIONS IN ADULTS WITH CONGENITAL HEART DISEASE
20230 citationsauthor #3
RELATIONSHIP OF SOCIAL DETERMINANTS OF HEALTH AND HOSPITALIZATIONS FOR ATRIAL FIBRILLATION: A NATIONWIDE READMISSIONS DATABASE STUDY
20220 citationsauthor #5
Abstract 68: Impact Of Health Related Social Needs On Sex-based Differences In Hospital Readmissions For Atrial Fibrillation
20220 citationsauthor #5
Healthcare resource utilization in patients with newly diagnosed atrial fibrillation in the United States
20227 citationsauthor #6
REGULARIZATION OF VENTRICULAR ACTIVATION DURING ATRIAL FIBRILLATION USING PARAHISIAN AND VENTRICULAR PACING
20220 citationsauthor #3
Abstract 14028: Predictors of Atrial Fibrillation Free Survival in Patients With Implantable Cardiac Devices
20220 citationsauthor #2
Abstract 13655: Relationship of Health-Related Social Needs, Social Determinants of Health, and Hospital Readmission Following Atrial Fibrillation Ablation
20222 citationsauthor #3
Electrocardiogram Belt System: Opportunity for Optimization?
20220 citationsauthor #1
Abstract 13500: Real-World Healthcare Resource Utilization Outcomes With Dronedarone versus Sotalol Following Ablation in Adults With Atrial Fibrillation
20220 citationsauthor #9
Abstract 13528: Sex Differences in Healthcare Resource Utilization in Patients With Atrial Fibrillation Receiving Dronedarone versus Sotalol Following Ablation
20220 citationsauthor #9
TOTAL 30-DAY MORTALITY IN MEDICARE BENEFICIARIES FOLLOWING CATHETER ABLATION FOR ATRIAL FIBRILLATION (2016-17)
20210 citationsauthor #5
US Antiarrhythmic Drug Treatment for Patients With Atrial Fibrillation: An Insurance Claims–Based Report
202112 citationsauthor #5
Practical Insight Into Anticoagulation for an Aging Population.
20200 citationsauthor #2
Abstract 341: Population-level Insights Into 30-day Mortality in Medicare Beneficiaries After Inpatient and Outpatient Catheter Ablation for Atrial Fibrillation
20200 citationsauthor #5
DELAYED VERSUS EARLY CARDIOVERSION FOR PATIENTS WITH UNCOMPLICATED ATRIAL FIBRILLATION META-ANALYSIS
20200 citationsauthor #6
Abstract 12593: Sex-related Differences in Health Care Utilization in Patients With Atrial Flutter
20200 citationsauthor #3
COMPARATIVE VARIATION IN HEALTH CARE RESOURCE UTILIZATION BETWEEN PATIENTS WITH ATRIAL FLUTTER ONLY VERSUS ATRIAL FIBRILLATION WITH OR WITHOUT ATRIAL FLUTTER
20190 citationsauthor #3
NATIONAL ECONOMIC COST BURDEN OF ATRIAL FLUTTER ONLY PATIENTS WITHOUT ATRIAL FIBRILLATION
20190 citationsauthor #3
Patient Diversity and Population Health-Related Cardiovascular Outcomes Associated with Warfarin Use in Atrial Fibrillation: An Analysis Using Administrative Claims Data
20185 citationsauthor #1
Hospitalizations and Costs in Primary Prevention ICD Recipients: Who Determines the Outcomes?
20170 citationsauthor #1
Impact of Warfarin on Atrial-Fibrillation Outcomes Related to Economic Consumption Patterns: Hospitalization, Cost, and Mortality may be Predictable and Modifiable at the Population Level
20160 citationsauthor #1
Patterns of Dofetilide Use for the Treatment of Atrial Fibrillation
20161 citationsauthor #5
Abstract 13939: Cardiac Resynchronization Improves Cardiac Sodium Channel mRNA Splicing Most in Patients With Severe Heart Failure
20160 citationsauthor #10
Time course of appropriate implantable cardioverter-defibrillator therapy and implications for guideline-based driving restrictions.
201515 citationsauthor #1
A case series of anomalous high pacing lead impedances in normally functioning leads
201512 citationsauthor #2
A Call for Appropriate Evidence and Outcomes-Based Use and Measurement of Anticoagulation for Atrial Fibrillation: Moving the Population Towards Improved Health Via Multiple Stakeholders
20155 citationsauthor #5
Shared risk factors for anticoagulation in nonvalvular atrial fibrillation: a dilemma in clinical decision making.
20143 citationsauthor #1
Cardiac Troponin Assessment Following Atrial Fibrillation Ablation: Implications for Chest Pain Evaluation
20140 citationsauthor #6
Abstract 203: Patterns of Dofetilide Use for the Treatment of Atrial Fibrillation
20140 citationsauthor #5
Health Care Burden of Dyspepsia Among Nonvalvular Atrial Fibrillation Patients
20143 citationsauthor #1
Abstract 9: The Relationship Between Patient Diversity and Warfarin Use in Atrial Fibrillation: A Ten-Year Perspective (2000-2010) on Cardiovascular Outcomes
20131 citationsauthor #1
Device advisory letters: readability and comprehension, patient-centered outcomes not to be "misunderstood".
20130 citationsauthor #1
Abstract 226: Impact of Gastrointestinal Disorders among Nonvalvular Atrial Fibrillation Patients on Healthcare Resource Usage and Costs
20130 citationsauthor #1
Abstract 140: Effectiveness Of Dronedarone Among US Patients With Atrial Fibrillation/Flutter In The Real-World Setting
20130 citationsauthor #1
Treatment targets in atrial fibrillation: "Is feeling better good enough?".
20130 citationsauthor #1
Effectiveness of VF induction with DC fibber versus conventional induction methods in patients on chronic amiodarone therapy
20133 citationsauthor #3
Abstract TP399: Incremental Healthcare Burden Associated with Dyspepsia Among Nonvalvular Atrial Fibrillation Patients: Implications for Anticoagulation Therapy
20130 citationsauthor #1
Abstract 225: Healthcare Burden Associated with Dyspepsia Among Nonvalvular Atrial Fibrillation Patients
20130 citationsauthor #1
Prospective evaluation of cinefluoroscopy and chest radiography for Riata lead defects: implications for future lead screening
20135 citationsauthor #5
Catheter Ablation of Atrial Fibrillation in Octogenarians: The Right “Medicine?”
20120 citationsauthor #1
Do the benefits of anti-arrhythmic drugs outweigh the associated risks? A tale of treatment goals in atrial fibrillation
20123 citationsauthor #1
Long‐Term Insertable Loop Monitors: How Much Should We Watch to Get an Answer (Diagnosis)?
20120 citationsauthor #1
Concepts in Disease Progression of Atrial Fibrillation and Implications for Medical Management
20121 citationsauthor #1
AMIODARONE AND SOTALOL IN ATRIAL FIBRILLATION: TREATMENT PERSISTENCE AND OCCURRENCE OF ADVERSE EVENTS IN THE REAL-WORLD SETTING
20110 citationsauthor #1
Estimation of Total Incremental Health Care Costs in Patients With Atrial Fibrillation in the United States
2011732 citationsauthor #1
Abstract 8809: Time Course of Appropriate ICD Therapy in Patients from the OMNI Registry: Implications for Duration of Driving Restriction.
20110 citationsauthor #1
One-year treatment persistence and potential adverse events among patients with atrial fibrillation treated with amiodarone or sotalol: a retrospective claims database analysis.
201117 citationsauthor #1
Predicting the Risk of Heart Failure Events and Subsequent Mortality: What Doth the Seer Know?
20101 citationsauthor #1
TOTAL HEALTHCARE COSTS AMONG ATRIAL FIBRILLATION PATIENTS IN THE UNITED STATES IN 2010
20100 citationsauthor #1
The impact of stored atrial rhythm diagnostics in permanent pacemakers and the management of atrial fibrillation: the Vitatron Selection AFm Registry study
20103 citationsauthor #1
ESTIMATION OF INCREMENTAL CARDIOVASCULAR HEALTHCARE COSTS IN PATIENTS WITH ATRIAL FIBRILLATION IN THE UNITED STATES
20100 citationsauthor #1
Cv4 Comparative Cost of Ablation in Atrial Fibrillation Patients Stratified by Procedural Success Versus Failure: Implications for Resource Utilization in Medicare-Aged Ablation Candidates in the United States
20100 citationsauthor #1
Total costs and atrial fibrillation ablation success or failure in medicare-aged patients in the United States
201018 citationsauthor #1
BIVENTRICULAR VERSUS LEFT VENTRICULAR PACING FOR CARDIAC RESYNCHRNOIZATION THERAPY: COMPARISON OF THE ACUTE HEMODYNAMIC RESPONSE AND OPTIMAL AV DELAY
20100 citationsauthor #6
Influence of structural heart disease on characteristics of atrial fibrillation recurrence in patients with dual-chamber pacemakers.
20094 citationsauthor #5
Acute Hemodynamic Effects of Atrial Pacing with Cardiac Resynchronization Therapy
200927 citationsauthor #6
A Novel Method for Sinus Node Modification and Phrenic Nerve Protection in Resistant Cases
200916 citationsauthor #2
Cost of atrial fibrillation in United States managed care organizations
200987 citationsauthor #1
Cost of Hospital Admission for Antiarrhythmic Drug Initiation in Atrial Fibrillation
200930 citationsauthor #1
Patterns and Predictors of Discontinuation of Rhythm‐Control Drug Therapy in Patients with Newly Diagnosed Atrial Fibrillation
200919 citationsauthor #1
National assessment of medicare prescription plan coverage gaps among patients with atrial fibrillation in the US
20093 citationsauthor #1
Catheter Ablation of Cardiac Arrhythmias, edited by Shoei K. Stephan Huang and Mark A. Wood, Elsevier
20070 citationsauthor #1
A Written Policy Increases Compliance With Guidelines for Therapeutic Anticoagulation Prior to Elective Direct Current Cardioversion of Atrial Fibrillation
20073 citationsauthor #2
Abstract 2430: Should All Octogenarians Who Meet Criteria Receive an Implantable Cardioverter Defibrillator?
20070 citationsauthor #5
A Prospective Comparison of AV Delay Programming Methods for Hemodynamic Optimization during Cardiac Resynchronization Therapy
2007112 citationsauthor #6
Value of Pacemaker Atrial Diagnostic Data in Patients with Paroxysmal Atrial Fibrillation: An Opportunity to Improve Rates of Warfarin Utilization
20077 citationsauthor #1
Association of ventricular arrhythmias detected by implantable cardioverter defibrillator and ambient air pollutants in the St Louis, Missouri metropolitan area
200697 citationsauthor #2
P2-91: Are atrial fibrillation recurrences different in patients with paroxysmal atrial fibrillation and structural heart disease?
20060 citationsauthor #3
Left bundle branch block during orthodromic reciprocating tachycardia: where is the accessory pathway?
20066 citationsauthor #1
Acute hemodynamic effect of overdrive atrial pacing during cardiac resynchronization therapy
20051 citationsauthor #4
Cardiac resynchronization therapy: a potential option for congenitally corrected transposition of the great vessels.
200516 citationsauthor #3
Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study.
200590 citationsauthor #10
877 A new automated algorithm for optimizing AV delay to improve global LV contractile function with cardiac resynchonization therapy
20050 citationsauthor #5
492 Structural heart disease increases duration and burden but not frequency of atrial fibrillation recurrence in patients with pacemakers
20050 citationsauthor #5
584 Does amiodarone affect efficacy of ventricular fibrillation induction with direct current fibber or T-wave shock?
20050 citationsauthor #1
748 Is nominal AV delay offset optimal for heart failure patients receiving cardiac resynchronization therapy
20050 citationsauthor #5
A new AV delay optimization algorithm increases LV global contractile function in CRT patients compared with echo derived methods of AV delay programming
20052 citationsauthor #5
A new automated algorithm for optimizing AV delay to improve global LV contractile function with cardiac resynchonization therapy
20057 citationsauthor #5
Polymorphic Ventricular Tachycardia with a Normal QT Interval Following Azithromycin
200556 citationsauthor #1
Occurrence and Characteristics of Stroke Events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) Study
2005157 citationsauthor #10
846-6 Amiodarone reduces major cardiovascular morbidity after cardiac surgery: Results of a meta-analysis
20040 citationsauthor #4
Cardiac pacing: the state of the art.
2004132 citationsauthor #2
Use patterns of low-molecular weight heparin and the impact on length of stay in patients hospitalized for atrial fibrillation.
200312 citationsauthor #1
Low molecular weight heparin in atrial fibrillation management: facts, fiction, future.
20037 citationsauthor #1
Use patterns of low-molecular weight heparin and the impact on length of stay in patients hospitalized for atrial fibrillation☆
20031 citationsauthor #1
Effect of amiodarone +/- diltiazem +/- beta blocker on frequency of atrial fibrillation, length of hospitalization, and hospital costs after coronary artery bypass grafting.
20029 citationsauthor #1
Atrial fibrillation after coronary surgery: comparison between different health care systems.
200218 citationsauthor #2
A prospective, randomized, controlled trial of an emergency department-based atrial fibrillation treatment strategy with low-molecular-weight heparin.
200233 citationsauthor #1
Importance of limiting atrial fibrillation after heart surgery
20020 citationsauthor #1
Effect of postoperative atrial fibrillation on length of stay after cardiac surgery (The Postoperative Atrial Fibrillation in Cardiac Surgery study [PACS(2)].
200187 citationsauthor #1
Time course and frequency of subtherapeutic anticoagulation for newly prescribed warfarin anticoagulation before elective cardioversion of atrial fibrillation or flutter.
200116 citationsauthor #1
Pharmacologic and nonpharmacologic approaches to the prevention of atrial fibrillation after heart surgery
20010 citationsauthor #1
Clinical outcomes and costs associated with a first episode of uncomplicated atrial fibrillation presenting to the emergency room.
200115 citationsauthor #1
Paroxetine reduced recurrent syncope in patients who were resistant to or intolerant of other drug therapy
19990 citationsauthor #2
Effects of β-Adrenergic Blocking Therapy on Left Ventricular Diastolic Relaxation Properties in Patients With Dilated Cardiomyopathy
199934 citationsauthor #1
FLOWS OF NEUTRALLY BUOYANT SUSPENSIONS IN SEVERAL VISCOMETERS
19887 citationsauthor #2
FLOW OF A SUSPENSION THROUGH A VERTICAL TUBE
19876 citationsauthor #1
THE LOCAL VOLUME-AVERAGED EQUATIONS OF MOTION FOR A SUSPENSION OF NON-NEUTRALLY BUOYANT SPHERES
198718 citationsauthor #2

TIMELINE

1987 24 citations

1988 7 citations

1999 34 citations

2001 118 citations

2002 60 citations

2003 20 citations

2004 132 citations

2005 329 citations

2006 103 citations

2007 122 citations

2009 186 citations

2010 22 citations

2011 749 citations

2012 4 citations

2013 9 citations

2014 6 citations

2015 32 citations

2016 1 citations

2017 0 citations

2018 5 citations

2019 0 citations

2020 0 citations

2021 12 citations

2022 9 citations

2023 24 citations

Michael H. Kim

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT